Emergency use authorization has not been granted to Serum Institute of India (SII) and Bharat Biotech’s Covid-19 vaccines over lack of data, sources told News18 on Wednesday.
Bharat Biotech had on Monday applied to the Drugs Controller General of India (DCGI) seeking emergency use authorisation for its Covid-19 vaccine Covaxin, which is being indigenously developed by the Hyderabad-based pharmaceutical firm in collaboration with the Indian Council of Medical Research (ICMR). The Pune-based SII had applied to the central drug regulator for emergency use authorisation of AstraZeneca-Oxford’s coronavirus vaccine.
#COVID19 #BharatBiotech #CoronavirusVaccine
Dear Readers,
As an independent media platform, we do not take advertisements from governments and corporate houses. It is you, our readers, who have supported us on our journey to do honest and unbiased journalism. Please contribute, so that we can continue to do the same in future.
As an independent media platform, we do not take advertisements from governments and corporate houses. It is you, our readers, who have supported us on our journey to do honest and unbiased journalism. Please contribute, so that we can continue to do the same in future.
